Neutrophil-to-lymphocyte ratio at diagnosis as a biomarker for survival of amyotrophic lateral sclerosis.

Amyotrophic lateral sclerosis & frontotemporal degeneration Pub Date : 2024-08-01 Epub Date: 2024-05-14 DOI:10.1080/21678421.2024.2351187

Robert J Nona, Robert D Henderson, Pamela A McCombe

{"title":"Neutrophil-to-lymphocyte ratio at diagnosis as a biomarker for survival of amyotrophic lateral sclerosis.","authors":"Robert J Nona, Robert D Henderson, Pamela A McCombe","doi":"10.1080/21678421.2024.2351187","DOIUrl":null,"url":null,"abstract":"Introduction: The neutrophil-to-lymphocyte ratio (NLR) has previously been reported to be associated with survival in ALS. To provide further information about the role of NLR as a biomarker in ALS, we performed a systematic review, analyzed data from our local cohort of ALS subjects and performed a meta-analysis.Methods: (1) The systematic review used established methods. (2) Using data from our cohort of subjects, we analyzed the association of NLR with survival. (3) Meta-analysis was performed using previous studies and our local data.Results: (1) In the systematic review, higher NLR was associated with shorter survival in all studies. (2) In our subjects, survival was significantly shorter in patients in the highest NLR groups. (3) Meta-analysis showed subjects with highest NLR tertile or with NLR >3 had significantly shorter survival than other subjects.Discussion: This study supports NLR as a biomarker in ALS; high NLR is associated with poor survival.","PeriodicalId":72184,"journal":{"name":"Amyotrophic lateral sclerosis & frontotemporal degeneration","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Amyotrophic lateral sclerosis & frontotemporal degeneration","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/21678421.2024.2351187","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/5/14 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: The neutrophil-to-lymphocyte ratio (NLR) has previously been reported to be associated with survival in ALS. To provide further information about the role of NLR as a biomarker in ALS, we performed a systematic review, analyzed data from our local cohort of ALS subjects and performed a meta-analysis.

Methods: (1) The systematic review used established methods. (2) Using data from our cohort of subjects, we analyzed the association of NLR with survival. (3) Meta-analysis was performed using previous studies and our local data.

Results: (1) In the systematic review, higher NLR was associated with shorter survival in all studies. (2) In our subjects, survival was significantly shorter in patients in the highest NLR groups. (3) Meta-analysis showed subjects with highest NLR tertile or with NLR >3 had significantly shorter survival than other subjects.

Discussion: This study supports NLR as a biomarker in ALS; high NLR is associated with poor survival.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

诊断时的中性粒细胞与淋巴细胞比率作为肌萎缩侧索硬化症存活率的生物标志物。

简介中性粒细胞与淋巴细胞比值（NLR）曾被报道与 ALS 患者的存活率有关。为了进一步了解 NLR 在 ALS 中作为生物标志物的作用，我们进行了一项系统综述，分析了本地 ALS 受试者队列中的数据，并进行了一项荟萃分析。方法：（1）系统综述采用既定方法。(2）利用我们队列中的受试者数据，分析 NLR 与生存的关系。(3）利用以前的研究和我们当地的数据进行元分析。结果：（1）在系统综述中，所有研究中较高的 NLR 与较短的生存期相关。(2）在我们的研究对象中，NLR最高组患者的生存期明显较短。(3）Meta 分析显示，NLR 最高三元组或 NLR >3 的受试者生存期明显短于其他受试者。讨论：本研究支持将 NLR 作为 ALS 的生物标志物；NLR 高与生存率低有关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Amyotrophic lateral sclerosis & frontotemporal degeneration

自引率

0.00%

发文量

期刊最新文献

ALSUntangled #76: Wahls protocol. Graph theory network analysis reveals widespread white matter damage in brains of patients with classic ALS. Alteration in ornithine metabolism due to mutation in ALDH18A1 masquerading as ALS in pregnancy. Multistep modeling applied to a Malaysian ALS registry. Assessing disease progression in ALS: prognostic subgroups and outliers.